Monte Rosa Therapeutics (GLUE) Revenue (2024 - 2026)

Monte Rosa Therapeutics' Revenue history runs 3 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Revenue fell 94.94% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 97.3% YoY), while the FY2025 annual figure was $123.7 million, up 63.54% from the prior year.
• Revenue was $4.3 million for Q1 2026 at Monte Rosa Therapeutics, up from $2.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $150.0 million in Q3 2025 to a low of $1.1 million in Q1 2024.
• Historically, Revenue has averaged $37.9 million across 3 years, with a median of $9.2 million in 2024.
• Biggest YoY gain for Revenue was 7882.05% in 2025; the steepest drop was 95.41% in 2025.
• A 3-year view of Revenue shows it stood at $60.6 million in 2024, then tumbled by 95.41% to $2.8 million in 2025, then surged by 54.62% to $4.3 million in 2026.
• The last three Revenue figures came in at $4.3 million (Q1 2026), $2.8 million (Q4 2025), and $150.0 million (Q3 2025), per Business Quant data.